Innovation

CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.

Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation. 

In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.

Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions. 

Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.

NVIDIA is further embedding itself in the biopharma industry. Its artificial intelligence tools are now more accessible, integrated and it is taking a strategic collaborative approach with competitors like Google to bolster AI-driven startups that ultimately use its tools. 

Creo Medical and Clinithink are among the healthtech innovators who have benefited from funding and advisory support offered by the Development Bank of Wales. All three gave a take on the current funding environment at BioWales in London 2024.

One of In Vivo's 2024 Rising Leaders, Hanadie Yousef, CEO of Juvena Therapeutics, talks about the secretome as a source of therapeutics, the company's lead assets, the future of longevity medicine and learning as you go as a biotech entrepreneur.  

With an engineer’s mind, Jason Park, CEO of Empress Therapeutics, has a unique take on problem solving for fundraising and the value of being a platform company focused on small molecules.

Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”

Protein misfolding diseases, such as Alzheimer’s, are still largely untreatable and incurable. A leading scientist explains why these diseases pose unique R&D challenges and how researchers are beginning to overcome them.

Royal Philips’ head of Enterprise Informatics Shez Partovi explains the rationale behind the 2023 decision to set up a vertical business for digital, AI and software applications, to operate alongside imaging, monitoring and interventional therapy.

Technical challenges and lackluster investor sentiment about the near-term commercial potential of cell and gene therapies in neurological disorders may be holding the field back.

In a breakthrough for drug discovery, quantum hardware outperformed classical hardware in generating two promising KRAS inhibitors.

Healthtech innovators are being asked by users and clinicians how technology solutions can increase health system efficiency and respond to concerns over staff shortages. Royal Philips’ Bert van Meurs fielded these questions at ECR 2024.

Nouscom, with one major partner and strong confidence, is building research and manufacturing foundations to address significant market needs with its neoantigen cancer vaccine platform.